Loratadine lingual spray

Drug Profile

Loratadine lingual spray

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator NovaDel Pharma
  • Class Antiallergics; Dibenzocycloheptenes; Nonsedating antihistamines; Piperidines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Seasonal allergic rhinitis

Most Recent Events

  • 15 Nov 2004 Suspended - Phase-II for Seasonal allergic rhinitis in USA (Transmucosal)
  • 15 Nov 2004 NovaDel Pharma has completed a Phase-II trial in Seasonal allergic rhinitis in the USA
  • 18 Feb 2003 Phase-II clinical trials in Seasonal allergic rhinitis in USA (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top